




MEMORANDUM

DATE: November 19, 2008

TO: Base Hospital:
ED Medical Directors
Nurse Managers
PLNs

FROM: Reza Vaezazizi, MD
ICEMA Medical Director 

SUBJECT: ZOFRAN (Ondansetron) TRIAL STUDY

I am pleased to announce ICEMA's participation in a trial study of Zofran (Ondansetron) in the pre-hospital setting. We are one of three EMS agencies in California approved by EMSA to participate in this study.

Please review the attached approved protocol for administration of Zofran in the pre-hospital setting. Paramedics are authorized to administer the first dose of Zofran prior to any base hospital contact. However, any additional doses will require base hospital contact and consultation with an MICN/base hospital physician. I encourage you to consider additional dosing of this medication when indicated and appropriate for patient's condition. The study is scheduled to last about 18 months.

Please review this new protocol with all of your MICN's and base hospital physicians. You may forward any questions or concerns to ICEMA, attention Sherri Shimshy at (909) 388-5816 or SShimshy@cao.sbcounty.gov.

I want to thank you for your help and participation in this project.

Attachment

RV/SS/mae

cc: Virginia Hastings, ICEMA Executive Director
SB County EMS Officers
ICEMA Medical Advisory Committee (MAC)

**NAUSEA AND VOMITING
ZOFRAN (Ondansetron)
PARAMEDIC TRIAL STUDY**

FIELD ASSESSMENT/TREATMENT INDICATORS:

1. Nausea
2. Vomiting

CONTRAINDICATIONS:

Known sensitivity to ondansetron or other 5-HT₃ antagonists:

1. Granisetron (Kytril)
2. Dolasetron (Anzemet)
3. Palonosetron (Aloxi)

PROCEDURE:

1. Assess patient for need for anti-emetic therapy
2. Maintain airway
3. Position of comfort
4. Oxygen

DOSAGE: PATENTS FOUR (4) YEARS OLD TO ADULT


1. Ondansetron 4mg IM or slow IV push (greater than 30 seconds)
2. Ondansetron 4mg Oral Disintegrating Tablet (ODT)
3. Base Hospital may order a repeat dose of ondansetron 4 mg for continuing nausea or vomiting

DOCUMENTATION:

Documentation will be done on the electronic patient care record (ePCR). Patient's response to the medication will be measured using the attached Visual Analog Scale for Nausea at fifteen (15) minute intervals after the administration and upon arrival at the receiving hospital. The patient's response and vital signs will be documented on the ePCR.


VISUAL ANALOG SCALE FOR NAUSEA

How severe is your nausea today? (Please mark on the line below)




(Post Treatment)

Which of the following best describes your nausea now?



ESCALA ANÁLOGA VISUAL PARA LA NÁUSEA

¿Qué severa está la náusea hoy día? (Por favor marque en la línea de abajo)



(Tratamiento Posterior)

¿Cuál de los siguientes ahora describe mejor su náusea?

